Rockville, Maryland’s American Gene Technologies (AGT) is on a mission to cure HIV. And they just achieved another important milestone in that potentially groundbreaking journey.
In early November 2021, the company announced that the third patient in its first-in-human study for AGT103-T, a cell therapy for HIV, had been dosed with no serious adverse events. This latest milestone achievement moves the company and its team another step closer to curing HIV and making history.
We’re excited to announce this year’s finalists for the second annual 2021 BioBuzz Awards. These awards celebrate the people and companies across our regional community and their efforts and accomplishments to impact human health and build a stronger biotech community.
There is a growing movement of professionals seeking jobs with a purpose. The mission-driven culture of a company is a powerful attraction for those value-driven prospective applicants. Curing HIV is one of the bolder missions to be found in the I-270 technology corridor. With its bold mission to develop a cure for HIV, American Gene Technologies Business Development head Norman Rogers said that it’s an “attractive position for people who want a front seat to history.”
Cell therapies have grown to become a prevailing field dominating new medical breakthroughs with the promise of treatments and cures for multiple diseases. The biopharma hubs of Philadelphia and Maryland have emerged as important drivers of this new wave of medicine, build on the foundation of renowned research institutes, universities, and a number of successful cell therapy companies who have paved the way forward in this field.
EPISODE SUMMARY
For more than a year now, COVID has been society’s focus—and rightly so. But today we turn our attention to another virus—HIV. After 40 years, there is still no cure or a vaccine for the disease. In this episode, we hear from Dr. Anthony Fauci and CEO of innovative company American Gene Technologies, Jeff Galvin, about the past, present, and future of HIV treatments and medications. Is there a cure on the horizon?
Guests:
Jeffrey Galvin, American Gene Technologies
Anthony Fauci, National Institute of Allergy and Infectious Diseases
EPISODE NOTES
For more than a year now, COVID has been society’s focus—and rightly so. But today we turn our attention to another virus—HIV. After 40 years, there is still no cure or a vaccine for the disease. In this episode, we hear from Dr. Anthony Fauci and CEO of innovative company American Gene Technologies, Jeff Galvin, about the past, present, and future of HIV treatments and medications. Is there a cure on the horizon?
Investors Eye Gene Therapy Companies and Rapidly Expanding Market – Five Publicly Traded Gene Therapy Companies
The BHCR has become a burgeoning center for cell therapy development and manufacturing. As a result, a host of cell therapy companies chose to locate themselves within the region to capitalize on its many advantages.
American Gene Technologies’ goal to develop a cure for HIV moved one step closer to reality. After infusing the first patient with its cell therapy candidate AGT103-T, the company announced the Data and Safety Monitoring Board unanimously supported the continuation of the clinical study without modification.
American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data revealed no adverse effects from the treatment. AGT’s Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease, is designed to induce durable viral suppression by delivering therapeutic genes to the recipient’s immune cells. The cells are collected by leukapheresis, modified outside the body, then re-infused. Once infused, the cells are expected to durably suppress the virus at undetectable levels without the need for antiretroviral treatment.
Rare moms Amber Freed, Brittany Stineman, and Illumina Genetic Counselor Holly Snyder will give you everything you need to know in this 1-hour live session.
